Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
Filetype[PDF-498.63 KB]


Details:
No Related Documents.
You May Also Like:
  1. Public Health Impact After the Introduction of PsA-TT: The First 4 Years
    Personal Author:
    Diomandé, Fabien V. K.; Djingarey, Mamoudou H.; Daugla, Doumagoum M.; Novak, Ryan T.; Kristiansen, Paul A.; Collard, Jean-Marc; Gamougam, Kadidja; Kandolo, Denis; Mbakuliyemo, Nehemie; Mayer, Leonard; Stuart, James; Clark, Thomas; Tevi-Benissan, Carol; Perea, William A.; Preziosi, Marie-Pierre; Marc LaForce, F.; Caugant, Dominique; Messonnier, Nancy; Walker, Oladapo; Greenwood, Brian;
    Published Date:
    Nov 15 2015
    Source:
    Clin Infect Dis. 2015; 61(Suppl 5):S467-S472.
    Description:
    During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.|The new vaccine effective...
    File Type:
    Filetype[PDF - 175.59 KB]
  2. Phylogenetic relationships and regional spread of meningococcal strains in the meningitis belt, 2011–2016
    Personal Author:
    Topaz, Nadav; Caugant, Dominique A.; Taha, Muhamed-Kheir; Brynildsrud, Ola Brønstad; Debech, Nadia; Hong, Eva; Deghmane, Ala-Eddine; Ouédraogo, Rasmata; Ousmane, Sani; Gamougame, Kadidja; Njanpop-Lafourcade, Berthe-Marie; Diarra, Seydou; Fox, LeAnne M.; Wang, Xin;
    Published Date:
    March 04 2019
    Source:
    EBioMedicine. 2019; 41:488-496
    Description:
    BackgroundHistorically, the major cause of meningococcal epidemics in the meningitis belt of sub-Saharan Africa has been Neisseria meningitidis serogroup A (NmA), but the incidence has been substantially reduced since the introduction of a serogroup ...
    File Type:
    Filetype[PDF - 1.31 MB]
  3. MMWR. Morbidity and mortality weekly report, Vol. 64, no. 41, October 23, 2015
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    October 23, 2015
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 64, no. 41
    File Type:
    Filetype[PDF - 1.16 MB]
  4. Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt
    Personal Author:
    Jackson, Michael L.; Diallo, Alpha Oumar; Médah, Isaie; Bicaba, Brice Wilfried; Yaméogo, Issaka; Koussoubé, Daouda; Ouédraogo, Rasmata; Sangaré, Lassané; Mbaeyi, Sarah A.;
    Published Date:
    Oct 25 2018
    Source:
    PLoS One. 13(10).
    Description:
    We previously developed a mathematical simulation of serogroup A Neisseria meningitidis (NmA) transmission in Burkina Faso, with the goal of forecasting the relative benefit of different vaccination programs. Here, we revisit key structural assumptio...
    File Type:
    Filetype[PDF - 1.03 MB]
  5. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014
    Personal Author:
    Djingarey, Mamoudou H.; Diomandé, Fabien V. K.; Barry, Rodrigue; Kandolo, Denis; Shirehwa, Florence; Lingani, Clement; Novak, Ryan T.; Tevi-Benissan, Carol; Perea, William; Preziosi, Marie-Pierre; LaForce, F. Marc;
    Published Date:
    Nov 15 2015
    Source:
    Clin Infect Dis. 2015; 61(Suppl 5):S434-S441.
    Description:
    A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African "meningitis belt" and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali, and Nig...
    File Type:
    Filetype[PDF - 347.17 KB]